Endeavor Resolute approved in EU:
This article was originally published in Clinica
Medtronic, of Minneapolis, Minnesota, has CE-marked the new form of its zotarolimus-eluting Endeavor stent for sale in the EU, enabling the device's launch in various non-US countries earlier than the company had originally expected. The Endeavor Resolute stent will be launched in more than 50 countries in Europe, Asia, the Middle East and Africa by the end of this year. The new stent is not approved in the US; the first-generation form of the device is expected to gain US approval by the end of 2007. Endeavor Resolute uses a biocompatible polymer called BioLinx, designed to extend the duration of drug exposure in the vessel.